Semax

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, which is a region of adrenocorticotropic hormone known to influence memory and attention. Unlike parent ACTH, Semax has been modified (with an added Pro-Gly-Pro extension) to increase stability and to eliminate the adrenal-stimulating (steroidogenic) activity. The result is a peptide that retains and enhances the cognitive/neuroprotective properties of the ACTH fragment without triggering cortisol release.

Yes. Semax has been registered as a pharmaceutical drug in Russia since 1994, where it is available as a nasal spray for indications including ischemic stroke recovery, cognitive impairment, optic nerve atrophy, and attention deficit. It is also approved in Ukraine. Outside Russia and Ukraine, it is not approved for any clinical use and remains a research compound. Western regulatory agencies (FDA, EMA) have not reviewed or approved Semax.

Intranasal administration bypasses the blood-brain barrier via the olfactory nerve and trigeminal pathways, allowing direct delivery to the CNS within minutes. This is the primary route used in Russian clinical protocols. When administered subcutaneously, Semax must cross the blood-brain barrier through systemic circulation. Studies suggest intranasal delivery achieves significantly higher CNS concentrations relative to dose, which is why intranasal is the preferred research route.

Brain-Derived Neurotrophic Factor (BDNF) is a protein that supports the survival, growth, and differentiation of neurons and synapses. Low BDNF levels are associated with depression, cognitive decline, Alzheimer's disease, and poor neurological recovery after injury. Semax upregulates both BDNF and NGF (Nerve Growth Factor) simultaneously—an effect that drives neuroplasticity, synaptic strengthening, and neuroprotection. The BDNF elevation is believed to underlie both Semax's cognitive benefits and its protective effects in stroke models.

Both Semax and Selank are Russian-developed neuropeptides approved domestically, but they differ in their primary focus. Semax is primarily nootropic/neuroprotective—enhancing cognition, BDNF, and protecting against brain injury. Selank is primarily anxiolytic—reducing anxiety and normalizing stress responses without sedation. Both affect BDNF and have some immunomodulatory properties. Selank is a Tuftsin analog; Semax is an ACTH analog. Some researchers study them together for complementary cognitive + anxiolytic effects.

Russian clinical trials and preclinical studies have documented Semax reducing infarct size in ischemia models, improving neurological scores, and accelerating functional recovery. A key mechanism is reducing excitotoxicity and oxidative stress during and after ischemic events. Clinical protocols in Russia use Semax intranasally (both during acute stroke and during rehabilitation phases) and report improved cognitive and motor outcomes versus standard care alone. These results are not replicated in large Western RCTs, however, and the quality of Russian clinical trial reporting varies.

Semax does not function like classical stimulants (which work by elevating catecholamines acutely). Its cognitive-enhancing effects build over days to weeks through neuroplasticity mechanisms—BDNF upregulation, synaptic remodeling, and gene expression changes. However, Semax does modulate dopaminergic and serotonergic neurotransmission (documented in a 2005 Neurochemical Research study), which may contribute to acute attentional improvements. Users typically report increased alertness without the crash or agitation associated with amphetamine-class stimulants.

Semax has a very short serum half-life (minutes after systemic injection) because the base ACTH(4-10) sequence is rapidly degraded by enkephalinase. The Pro-Gly-Pro extension in Semax inhibits enkephalinase, extending its effective duration compared to the unmodified fragment. Despite rapid clearance from plasma, CNS effects (particularly BDNF elevation) persist hours to days after dosing. Russian protocols typically use once-daily or twice-daily intranasal dosing, and some research cycles use consecutive daily administration for 5–10 days with breaks.

Some Russian research protocols combine Semax and Selank for complementary effects — Semax for cognitive enhancement and neuroprotection, Selank for anxiolysis and immune modulation. Both share the Pro-Gly-Pro extension and intranasal delivery route. No published head-to-head or combination trials with controlled methodology exist in Western literature, so the evidence base for combined use is limited to Russian clinical observations and individual case reports. The peptides act through distinct primary receptors and pathways, which theoretically supports a combination approach.

Semax was developed at the Russian Academy of Sciences and has been commercially available in Russia since 1994. Most clinical trials were conducted within the Russian healthcare system and published in Russian journals such as Zhurnal Nevrologii i Psikhiatrii. This limits Western access and independent evaluation. The research quality varies: some studies meet international standards with proper controls and blinding, while others lack the methodological rigor expected by FDA or EMA. Researchers interested in Semax should note that while the pharmacological effects are well-documented in animal models (published in international journals), the clinical evidence remains predominantly Russian.